72. Godal HC, Madsen K, Nissen-Meyer R. Thromboembolism in patients with total proconvertin deficiency. A report of two cases. Acta Med Scand. 1962;171:325-327.
73. Mariani G, Herrmann FH, Schulman S, et al. Thrombosis in inherited factor VII deficiency. J Thromb Haemost. 2003;1:2153-2158.
74. Seligsohn U, Zivelin A, Zwang E. Combined factor V and factor VIII deficiency among non-Ashkenazi Jews. N Engl J Med. 1982;307:1191-1195.
75. Bolton-Maggs PH, Young Wan-Yin B, McCraw AH, Slack J, Kernoff PB. Inheritance and bleeding in factor XI deficiency. Br J Haematol. 1988;69: 521-528.
76. Neerman-Arbez M, Vu D, Abu-Libdeh B, Bouchardy I, Morris MA. Prenatal diagnosis for congenital afibrinogenemia caused by a novel nonsense mutation in the FGB gene in a Palestinian family. Blood. 2003;101:3492-3494.
77. Di Paola J, Nugent D, Young G. Current therapy for rare factor deficiencies. Haemophilia. 2001: 7(suppl 1):16-22.
78. Tabor E, Epstein JS. NAT screening of blood and plasma donations: evolution of technology and regulatory policy. Transfusion. 2002;42:1230-1237.
79. Klein HG, Dodd RY, Dzik WH, et al. Current status of solvent/detergent-treated frozen plasma. Transfusion. 1998;38:102-107.
80. Riggert J, Humpe A, Legler TJ, et al. Filtration of methylene blue-photooxidized plasma: influence on coagulation and cellular contamination. Transfusion. 2001;41:82-86.
81. Llewelyn CA, Hewitt PE, Knight RS. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet. 2004;363:417-421.
82. Chuansumrit A, Mahaphan W, Pintadit P, et al. Combined factor V and factor VIII deficiency with congenital heart disease: response to plasma and DDAVP infusion. Southeast Asian J Trop Med Public Health. 1994;25:217-220.
83. Bauduer F, Guichandut JP, Ducout L. Successful use of fresh frozen plasma and desmopressin for transurethral prostatectomy in a French Basque with combined factors V+VIII deficiency. J Thromb Haemost. 2004;2:675-676.
84. Scharrer I. Recombinant factor VIIa for patients with inhibitors to factor VIII or IX or factor VII deficiency. Haemophilia. 1999;5:253-259.
85. Mariani G, Testa MG, Di Paolantonio T, Molskov BR, Hedner U. Use of recombinant, activated factor VII in the treatment of congenital factor VII deficiencies. Vox Sang. 1999;77:131-136.
86. Mariani G, Mannucci PM, Mazzucconi MG, Capitanio A. Treatment of congenital factor VII deficiency with a new concentrate. Thromb Haemost. 1978;39:675-682.
87. Cohen LJ, McWilliams NB, Neuberg R, et al. Prophylaxis and therapy with factor VII concentrate (human) immuno, vapor heated in patients with congenital factor VII deficiency: a summary of case reports. Am J Hematol. 1995;50:269-276.
88. Bolton-Maggs PH, Wensley RT, Kernoff PB, et al. Production and therapeutic use of a factor XI concentrate from plasma. Thromb Haemost. 1992; 67:314-319.
89. Bolton-Maggs PH, Colvin BT, Satchi BT, Lee CA, Lucas GS. Thrombogenic potential of factor XI concentrate. Lancet. 1994;344:748-749.
90. Mannucci PM, Bauer KA, Santagostino E, et al. Activation of the coagulation cascade after infusion of a factor XI concentrate in congenitally deficient patients. Blood. 1994;84:1314-1319.
91. Richards EM, Makris MM, Cooper P, Preston FE. In vivo coagulation activation following infusion of highly purified factor XI concentrate. Br J Haematol. 1997;96:293-297.
92. Rodeghiero F, Castaman GC, Di Bona E, Ruggeri M, Dini E. Successful pregnancy in a woman with congenital factor XIII deficiency treated with substitutive therapy. Report of a second case. Blut. 1987;55:45-48.
93. Brackmann HH, Egbring R, Ferster A, et al. Pharmacokinetics and tolerability of factor XIII concentrates prepared from human placenta or plasma: a crossover randomised study. Thromb Haemost. 1995;74:622-625.
94. Winkelman L, Sims GE, Haddon ME, et al. A pasteurized concentrate of human plasma factor XIII for therapeutic use. Thromb Haemost. 1986;55:402-405.
95. Reynolds TC, Butine M, Visich JE, et al. A randomized, placebo-controlled, double-blind, multidose study of the safety and pharmacokinetics of recombinant factor XIII administration in healthy volunteers [abstract]. Blood. 2003:102:98b.
96. Seitz R, Duckert F, Lopaciuk S, Muszbek L, Rodeghiero F, Seligsohn U. ETRO Working Party on Factor XIII questionnaire on congenital factor XIII deficiency in Europe: status and perspectives. Study Group. Semin Thromb Hemost. 1996,22: 415-418.
97. Salomon O, Zivelin A, Livnat T, et al. Prevalence, causes, and characterization of factor XI inhibitors in patients with inherited factor XI deficiency. Blood. 2003;101:4783-4788.

Erratum

In the article by Alberich Jordà et al entitled "The peripheral cannabinoid receptor Cb2, frequently expressed on AML blasts, either induces a neutrophilic differentiation block or confers abnormal migration properties in a ligand-dependent manner," which appeared in the July 15, 2004, issue of *Blood* (Volume 104:526-534), part of Figure 3A was missing. The complete panel 3A is shown below.